|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Metformin
gptkb:Dapagliflozin
|
|
gptkbp:activities
|
gptkb:physicist
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Trulicity
|
|
gptkbp:class
|
antidiabetic agent
|
|
gptkbp:clinical_trial
|
Phase 3
chronic management of diabetes
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
gptkb:medullary_thyroid_carcinoma
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
pre-filled pen
|
|
gptkbp:education
|
diet and exercise
monitoring blood sugar
injection technique
|
|
gptkbp:frequency
|
once a week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dulaglutide
|
|
gptkbp:indication
|
weight management
|
|
gptkbp:ingredients
|
gptkb:Dulaglutide
C172 H265 N43 O51 S
|
|
gptkbp:interacts_with
|
gptkb:Company
sulfonylureas
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:lifespan
|
5 days
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
glucose-dependent insulin secretion
once-weekly dosing
|
|
gptkbp:population
|
adults
|
|
gptkbp:provides_information_on
|
recommended for type 2 diabetes
|
|
gptkbp:research_focus
|
patient quality of life
mechanism of action studies
drug interactions
real-world evidence studies
safety in special populations
long-term cardiovascular outcomes
renal outcomes
weight loss efficacy
health economic evaluations
comparative effectiveness studies
compliance and adherence
|
|
gptkbp:safety_features
|
gptkb:2019
|
|
gptkbp:side_effect
|
nausea
abdominal pain
vomiting
diarrhea
hypoglycemia
pancreatitis
kidney injury
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:traded_on
|
gptkb:Trulicity
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
249.3 k Da
|